MedTrace Logo

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

NCT00476268 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 824

Last updated 2024-10-31

No results posted yet for this study

Summary

Efficacy and tolerability of the fixed combination beclometasone/formoterol in patients with moderate to severe persistent asthma.

Conditions

Interventions

DRUG

beclomethasone/formoterol (100/6µg) pMDI

Two puffs b.i.d

DRUG

Beclometasone dipropionate 250 µg/unit dose pMDI

2 inhalations bid

DRUG

Formoterol powder 12 µg/unit dose

2 inhalations bid

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • Francoise Bonnet-Gonod · Chiesi Farmaceutici

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2005-01-31
Completion
2005-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00476268 on ClinicalTrials.gov